MBX Biosciences

MBX Biosciences is a company listed under the stock ticker MBX (US).

View the org chart displaying its 16 main executives

Most searched biographies at MBX Biosciences

• Kent Hawryluk, Chief Executive Officer
• James Cornelius, Director
• Ora Hirsch Pescovitz, Director

Popular executive movements at MBX Biosciences

• Steven Ryder has joined the company as Director  (posted on February 6 2024).
• Michelle Graham has joined the company as Chief Human Resources Officer  (posted on November 1 2023).

Create your alert
to follow the executive moves at MBX Biosciences.

MBX Biosciences has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
• WindRose Health Investors has announced the acquisition of SubjectWell  (posted on May 2 2024).
• Enlaza Therapeutics has just announced a $100 Million fundraising (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by MBX Biosciences

• MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference | MBX Biosciences
• MBX Biosciences to Participate in Stifel 2023 Healthcare Conference | MBX Biosciences
• MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer | MBX Biosciences
• MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting | MBX Biosciences
• MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia | MBX Biosciences
• MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting | MBX Biosciences
• MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults | MBX Biosciences
• MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia | MBX Biosciences
• MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer | MBX Biosciences
• MBX Biosciences to Participate in Jefferies Healthcare Conference | MBX Biosciences
• View more press releases Close

Social media about MBX Biosciences

• MBX Biosciences on Wikipedia, Google News & Yahoo Finance
• MBX Biosciences on LinkedIn, Twitter & YouTube

Contact by email its executives including Kent Hawryluk

Call MBX Biosciences at +1 317...

View the org chart

Register to receive your alert

Report an error